ESSA Pharma Inc
NASDAQ:EPIX
Intrinsic Value
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of EPIX.
Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.
Sign up
to access ESSA Pharma Inc's intrinsic value history.
No restrictions, no limits.
All stocks, all tools.
Look for stocks that have been historically overvalued but are now trading below their intrinsic value.
Avoid stocks that are always undervalued and never reach their intrinsic value.
Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.
There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.
DCF Value
Discounted Cash Flow
Fundamental Analysis
Balance Sheet Decomposition
ESSA Pharma Inc
| Current Assets | 153m |
| Cash & Short-Term Investments | 152m |
| Receivables | 133k |
| Other Current Assets | 688k |
| Non-Current Assets | 360k |
| PP&E | 95.2k |
| Other Non-Current Assets | 265k |
| Current Liabilities | 3.4m |
| Accounts Payable | 2.1m |
| Accrued Liabilities | 1.4m |
EPIX Profitability Score
Profitability Due Diligence
ESSA Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
Score
ESSA Pharma Inc's profitability score is 36/100. The higher the profitability score, the more profitable the company is.
EPIX Solvency Score
Solvency Due Diligence
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
ESSA Pharma Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EPIX Price Targets Summary
ESSA Pharma Inc
According to Wall Street analysts, the average 1-year price target for
EPIX
is 19.79 USD
with a low forecast of 15.15 USD and a high forecast of 28.35 USD.
Ownership
EPIX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
EPIX Price
ESSA Pharma Inc
| Average Annual Return | 66.75% |
| Standard Deviation of Annual Returns | 89.24% |
| Max Drawdown | -96% |
| Market Capitalization | 136m USD |
| Shares Outstanding | 44 092 374 |
| Percentage of Shares Shorted | 0.11% |
Company Profile
ESSA Pharma Inc
Country
Industry
Market Cap
Dividend Yield
Description
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
